Immunai
PrivateLast Round
Series B
Oct 27, 2021
Est. Valuation
$1B
Total Funding Raised
$295M
Momentum
Top 10%
of companies Caplight tracks
Company Overview
Immunai is a biotechnology company that leverages artificial intelligence and single-cell genomics to map the immune system for the development of targeted immunomodulatory therapeutics.
Sector
Healthcare & Life Sciences
Verticals
Drug Discovery, Biotechnology, Medical AI, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting, Data as a Service, Revenue Share
AI Layer
Infrastructure
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Immunai Comparables
Compare Immunai with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Insitro | 84% | |
| Owkin | 83% | |
| IMU Biosciences | 81% |
Immunai Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Oct 27, 2021 | ||||
| Series A | Feb 11, 2021 | ||||
| Seed | May 14, 2020 |
Key People
Founding team and executive leadership
Immunai Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| ICON | Series B |
| Duquesne Family Office | Series A |
| Koch-ventures.com | Series B |
| Gefen Capital | Series B, Series A |
| Charles and Lynn Schusterman Family Philanthropies | Series A |
| Schusterman Family Investments | Series A |
| Catalio Capital Management | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 21, 2026
Monthly visitors grew 39% MoM.
- Jan 15, 2026
Partnered with Bristol Myers Squibb on a strategic collaboration.
Immunai Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Immunai's valuation, stock price, and market status.
Is Immunai a public or private company?
Immunai is a private company.
What is the current stock price of Immunai?
Immunai is a private company with no public stock price. No recent secondary market data is available.
How much is Immunai worth (valuation)?
Immunai's valuation is estimated at $1.0B based on funding round data.
Can I buy Immunai stock?
Immunai shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was Immunai's last funding round?
Immunai's most recent funding round was Series B on October 27, 2021.
Who are the main investors in Immunai?
Key investors in Immunai include Duquesne Family Office, Koch-ventures.com, Schusterman Family Investments, Catalio Capital Management, TLV Partners.
Will Immunai IPO soon?
No public IPO plans have been announced for Immunai.
How can I track Immunai secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Immunai's secondary market activity and sign up for updates.